Zai Lab Limited

NASDAQ:ZLAB

Biotechnology

Healthcare
$22.11 +3.42%

+$0.61 today

Market cap
$2.49B
Beta
0.78
P/E (TTM)
-11.4
EPS (TTM)
-$0.16
52W Low $15.96High $41.20

Volume 1.04M

Average 0.87M

ZLAB Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

Zai Lab LimitedNASDAQ: ZLAB

Deferred Revenue · Q2 FY2026 · quarter ended Jun 2026

Deferred revenue remains negative

Q2 FY2026 deferred revenue was $27.5M, compared with $0 a year earlier.

Context

  • Deferred revenue amounted to 2.6% of total assets at the end of Q2 FY2026, up 2.6 pp from a year earlier.
  • Deferred revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$27.5M— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoJun 2025
$0— since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Deferred Revenue vs competitors

How ZLAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred revenue is compared through growth and share of total assets rather than absolute size.
  • Deferred revenue amounts to 2.6% of total assets for ZLAB, versus a peer median of 0.0%.
ZLAB Competitors
Deferred Revenue for ZLAB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AAPGAscentage Pharma Group InternationalDec 2025CN¥37.51M CNY-30.6%+15.5%0.9%
ZLABZai Lab LimitedJun 2026$27.5M USD——2.6%
HCMHUTCHMED (China) LimitedDec 2025$0 USD—+33.0%0.0%
ANLAdlai Nortye Ltd.Dec 2025$0 USD-100.0%—0.0%
Peer median (excluding ZLAB) —-65.3%+24.3%0.0%

Competitors are the stored peer set for ZLAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents964.1M1.01B790.15M449.67M679.57M
Short-term Investments445M016.3M330M10M
Net Receivables54.81M48.57M65.33M89.41M106.12M
Inventory18.95M31.62M44.83M39.88M74.75M
Other Current Assets035.67M23M141.53M148.85M
Total Current Assets1.5B1.12B939.61M1.05B1.02B
Property, Plant & Equipment (Net)58.28M78.77M68.69M69.48M66.54M
Goodwill00000
Intangible Assets9.66M8.4M16.46M58.93M76.14M
Long-term Investments15.61M6.43M9.22M3.12M0
Tax Assets00003.39M
Other Non-current Assets25.53M2.2M2.32M3.75M7.02M
Total Non-current Assets109.08M95.8M96.69M135.27M153.1M
Total Assets1.61B1.22B1.04B1.19B1.17B
Account Payables126.16M65.97M112.99M100.91M141.61M
Short-term Debt000131.71M204.53M
Tax Payables8.82M13.28M16.99M5.15M0
Deferred Revenue00000
Other Current Liabilities4.42M4.05M5.35M6.35M7.07M
Total Current Liabilities192.9M139.84M203.07M299.39M416.17M
Long-term Debt000013.39M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)27.49M21.36M28.74M31.43M0
Other Non-current Liabilities00325K325K27.33M
Total Non-current Liabilities37.1M34.7M37.11M45.47M40.72M
Total Liabilities230M174.55M240.18M344.86M456.88M
Common Stock6K6K6K7K7K
Retained Earnings(1.42B)(1.86B)(2.2B)(2.45B)(2.63B)
Accumulated OCI(23.65M)25.69M37.63M50.52M29.7M
Other Stockholders Equity00000
Minority Interest00000
Total Equity1.38B1.05B796.12M840.9M715.5M
Total Debt15.54M20.39M15.15M153.47M224.26M
Net Debt(948.56M)(988.08M)(775M)(296.2M)(455.31M)

Zai Lab Limited

NASDAQ:ZLAB

Intrinsic Alpha fair value

Locked

Current Price

$22.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.